# Biotech Daily Digest — 2025-12-08

**32 items from 5 sources**

## Summary by Source

- Eli Lilly Press Releases: 1 item
- Endpoints News: 5 items
- Fierce Biotech: 6 items
- Regeneron Press Releases: 1 item
- arXiv q-bio: 19 items


## Eli Lilly Press Releases

- **[Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)](https://investor.lilly.com/news-releases/news-release-details/lillys-jaypirca-pirtobrutinib-met-its-primary-endpoint-first-its)**  
  _Sun, 07 Dec 2025 16:30:00 -0500_  
  In addition to meeting the primary endpoint of non-inferiority for  overall response rate (ORR) in the BRUIN CLL-314 study, pirtobrutinib achieved a numerically higher ORR of 87.0% compared to  78.5% for ibrutinib in the intent-to-treat (ITT) population Progression-free survival data were immature


## Endpoints News

- **[Structure Therapeutics’ obesity pill stacks up with Novo and Lilly; Ascletis also reports early results](https://endpoints.news/structure-therapeutics-obesity-pill-stacks-up-with-novo-and-lilly-ascletis-also-reports-early-results/)**  
  _Mon, 08 Dec 2025 14:04:26 +0000_  
  Structure Therapeutics' GLP-1 pill cut patients’ body weight by a placebo-adjusted average of 11.3% at around eight and a half months.

 This is competitive with both Eli Lilly’s orforglipron and Novo Nordisk’s oral formulation of ...

- **[Wave Life Sciences says its RNA obesity shot cuts fat, retains muscle](https://endpoints.news/wave-life-sciences-says-its-rna-obesity-shot-cuts-fat-but-retains-muscle/)**  
  _Mon, 08 Dec 2025 12:30:29 +0000_  
  Wave Life Sciences’ obesity therapy helped patients lose more fat mass and retain more muscle than low doses of Novo Nordisk’s Wegovy or Eli Lilly’s muscle-sparing candidate bimagrumab when compared across different clinical trials.  ...

- **[Kymera's pill looks competitive to Dupixent in Phase 1b eczema study](https://endpoints.news/kymeras-pill-looks-competitive-to-dupixent-in-phase-1b-eczema-study/)**  
  _Mon, 08 Dec 2025 12:00:59 +0000_  
  Kymera Therapeutics' pill showed Dupixent-like efficacy in a small Phase 1b study of eczema patients, the biotech announced Monday, in what could be a formidable challenger to one of biopharma's best-selling medicines.

 The early-stage study ...

- **[Kallyope heads to Phase 3 with migraine drug after mid-stage success](https://endpoints.news/kallyope-heads-to-phase-3-with-migraine-drug-after-mid-stage-success/)**  
  _Mon, 08 Dec 2025 11:30:40 +0000_  
  A decade-old New York City biotech has finally found success in treating acute migraine.

 On Monday, Kallyope said that its experimental migraine drug elismetrep succeeded in a Phase 2b trial that ...

- **[#ASH25: Star Therapeutics details early data for blood disorder shot, weighs IPO](https://endpoints.news/ash25-star-therapeutics-details-early-data-for-blood-disorder-shot-weighs-ipo/)**  
  _Sun, 07 Dec 2025 21:57:35 +0000_  
  ORLANDO, Fla. — Star Therapeutics said its once-a-month injection for von Willebrand disease substantially cut bleeding rates in a preliminary study, and is thinking about the next moves to complete a larger trial and eventually ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/biotech/chinas-ascletis-reports-77-weight-loss-oral-glp-1-contender-us-phase-2-study" hreflang="en">China's Ascletis reports 7.7% weight loss for oral GLP-1 contender in US phase 2 study</a>](https://www.fiercebiotech.com/biotech/chinas-ascletis-reports-77-weight-loss-oral-glp-1-contender-us-phase-2-study)**  
  _Dec 8, 2025 7:44am_  
  Ascletis Pharma has posted 7.7% weight loss for the highest dose of its own entrant in the highly contested oral GLP-1 race.

- **[<a href="https://www.fiercebiotech.com/biotech/biontechs-ctla-4-drug-improves-survival-phase-3-cancer-trial-poses-tolerability-challenge" hreflang="en">BioNTech's CTLA-4 drug improves survival in phase 3 cancer trial but poses tolerability challenge</a>](https://www.fiercebiotech.com/biotech/biontechs-ctla-4-drug-improves-survival-phase-3-cancer-trial-poses-tolerability-challenge)**  
  _Dec 8, 2025 7:47am_  
  A closer look at phase 3 data on BioNTech and OncoC4’s anti-CTLA-4 antibody has shown the efficacy that excited analysts last week is offset by a challenging tolerability profile.

- **[<a href="https://www.fiercebiotech.com/research/amphistas-targeted-glue-sticks-landing-aml-test-supporting-push-clinic" hreflang="en">Amphista's targeted glue sticks the landing in AML test, supporting push into the clinic</a>](https://www.fiercebiotech.com/research/amphistas-targeted-glue-sticks-landing-aml-test-supporting-push-clinic)**  
  _Dec 8, 2025 5:17am_  
  Amphista Therapeutics has reported preclinical leukemia data on its protein degrader, positioning the Big Pharma-partnered biotech to target a 2026 start date for a phase 1 clinical trial.

- **[<a href="https://www.fiercebiotech.com/biotech/abbvie-hands-back-phase-1-duties-chronic-inflammation-drug-partner-ose" hreflang="en">AbbVie hands back phase 1 duties for chronic inflammation drug to partner Ose</a>](https://www.fiercebiotech.com/biotech/abbvie-hands-back-phase-1-duties-chronic-inflammation-drug-partner-ose)**  
  _Dec 8, 2025 5:42am_  
  Close to two years after AbbVie handed over $48 million for the rights to Ose Immunotherapeutics’ inflammation drug, the Big Pharma now wants the French biotech to keep an eye on the asset for a while longer.

- **[<a href="https://www.fiercebiotech.com/biotech/ash-anito-cel-strengthens-best-class-potential-kite-preps-launch" hreflang="en">ASH: Anito-cel strengthens best-in-class potential as Gilead's Kite preps for launch</a>](https://www.fiercebiotech.com/biotech/ash-anito-cel-strengthens-best-class-potential-kite-preps-launch)**  
  _Dec 7, 2025 11:33am_  
  ORLANDO, Fla.—The leader of Gilead’s Kite Pharma is sure that anito-cel, the biotech’s next-generation multiple myeloma CAR-T challenger to Carvykti, is ready for prime time—and that the company is ready to bring CAR-T to the masses.

- **[<a href="https://www.fiercebiotech.com/biotech/ash-star-antibody-sparkles-preview-potential-phase-3-bleeding-disease-success" hreflang="en">ASH: Star antibody sparkles in preview of potential phase 3 bleeding disease success</a>](https://www.fiercebiotech.com/biotech/ash-star-antibody-sparkles-preview-potential-phase-3-bleeding-disease-success)**  
  _Dec 6, 2025 5:08pm_  
  ORLANDO, Fla.—With dosing underway in a pivotal phase 3 trial, Star Therapeutics is illuminating the clinical potential of its anti-bleeding antibody VGA039 with encouraging phase 1/2 results in a common bleeding disorder.


## Regeneron Press Releases

- **[Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment](https://investor.regeneron.com/news-releases/news-release-details/lynozyfictm-linvoseltamab-monotherapy-newly-diagnosed-multiple)**  
  _Sun, 07 Dec 2025 16:30:00 -0500_  
  All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial response or better) of ≥70% despite limited follow-up; evidence shows that these responses are expected to deepen over time Across all dose groups, 95% (19 of 20 patients) of all


## arXiv q-bio

- **[Exactly Solvable Population Model with Square-Root Growth Noise and Cell-Size Regulation](https://arxiv.org/abs/2512.05190)**  
  _Mon, 08 Dec 2025 00:00:00 -0500_  
  arXiv:2512.05190v1 Announce Type: new 
Abstract: We analyze a size-structured branching process in which individual cells grow exponentially according to a Feller square-root process and divide under general size-control mechanisms. We obtain exact expressions for the asymptotic population growth rate, the steady-stat…

- **[Peakspan: Defining, Quantifying and Extending the Boundaries of Peak Productive Lifespan](https://arxiv.org/abs/2512.05208)**  
  _Mon, 08 Dec 2025 00:00:00 -0500_  
  arXiv:2512.05208v1 Announce Type: new 
Abstract: The unprecedented extension of the human lifespan necessitates a parallel evolution in how we quantify the quality of aging and its socioeconomic impact. Traditional metrics focusing on Healthspan (years free of disease) overlook the gradual erosion of physiological cap…

- **[STAR-GO: Improving Protein Function Prediction by Learning to Hierarchically Integrate Ontology-Informed Semantic Embeddings](https://arxiv.org/abs/2512.05245)**  
  _Mon, 08 Dec 2025 00:00:00 -0500_  
  arXiv:2512.05245v1 Announce Type: new 
Abstract: Accurate prediction of protein function is essential for elucidating molecular mechanisms and advancing biological and therapeutic discovery. Yet experimental annotation lags far behind the rapid growth of protein sequence data. Computational approaches address this gap…

- **[Competition, stability, and functionality in excitatory-inhibitory neural circuits](https://arxiv.org/abs/2512.05252)**  
  _Mon, 08 Dec 2025 00:00:00 -0500_  
  arXiv:2512.05252v1 Announce Type: new 
Abstract: Energy-based models have become a central paradigm for understanding computation and stability in both theoretical neuroscience and machine learning. However, the energetic framework typically relies on symmetry in synaptic or weight matrices - a constraint that exclude…

- **[Tree Thinking in the Genomic Era: Unifying Models Across Cells, Populations, and Species](https://arxiv.org/abs/2512.05499)**  
  _Mon, 08 Dec 2025 00:00:00 -0500_  
  arXiv:2512.05499v1 Announce Type: new 
Abstract: The ongoing explosion of genome sequence data is transforming how we reconstruct and understand the histories of biological systems. Across biological scales, from individual cells to populations and species, trees-based models provide a common framework for representin…

- **[SSDLabeler: Realistic semi-synthetic data generation for multi-label artifact classification in EEG](https://arxiv.org/abs/2512.05500)**  
  _Mon, 08 Dec 2025 00:00:00 -0500_  
  arXiv:2512.05500v1 Announce Type: new 
Abstract: EEG recordings are inherently contaminated by artifacts such as ocular, muscular, and environmental noise, which obscure neural activity and complicate preprocessing. Artifact classification offers advantages in stability and transparency, providing a viable alternative…

- **[Decoding Selective Auditory Attention to Musical Elements in Ecologically Valid Music Listening](https://arxiv.org/abs/2512.05528)**  
  _Mon, 08 Dec 2025 00:00:00 -0500_  
  arXiv:2512.05528v1 Announce Type: new 
Abstract: Art has long played a profound role in shaping human emotion, cognition, and behavior. While visual arts such as painting and architecture have been studied through eye tracking, revealing distinct gaze patterns between experts and novices, analogous methods for auditor…

- **[Physics-Guided Surrogate Modeling for Machine Learning-Driven DLD Design Optimization](https://arxiv.org/abs/2512.05649)**  
  _Mon, 08 Dec 2025 00:00:00 -0500_  
  arXiv:2512.05649v1 Announce Type: new 
Abstract: Sorting cells based on their mechanical properties is essential for applications in disease diagnostics, cell therapy, and biomedical research. Deterministic Lateral Displacement (DLD) devices provide a label-free method for achieving such sorting, but their performance…

- **[Emergence of Language in the Developing Brain](https://arxiv.org/abs/2512.05718)**  
  _Mon, 08 Dec 2025 00:00:00 -0500_  
  arXiv:2512.05718v1 Announce Type: new 
Abstract: A few million words suffice for children to acquire language. Yet, the brain mechanisms underlying this unique ability remain poorly understood. To address this issue, we investigate neural activity recorded from over 7,400 electrodes implanted in the brains of 46 child…

- **[DeeDeeExperiment: Building an infrastructure for integrating and managing omics data analysis results in R/Bioconductor](https://arxiv.org/abs/2512.05731)**  
  _Mon, 08 Dec 2025 00:00:00 -0500_  
  arXiv:2512.05731v1 Announce Type: new 
Abstract: Summary: Modern omics experiments now involve multiple conditions and complex designs, producing an increasingly large set of differential expression and functional enrichment analysis results. However, no standardized data structure exists to store and contextualize th…

- **[Fluctuating Environments Favor Extreme Dormancy Strategies and Penalize Intermediate Ones](https://arxiv.org/abs/2512.05856)**  
  _Mon, 08 Dec 2025 00:00:00 -0500_  
  arXiv:2512.05856v1 Announce Type: new 
Abstract: Dormancy is a widespread adaptive strategy that enables populations to persist in fluctuating environments, yet how its benefits depend on the temporal structure of environmental variability remains unclear. We examine how dormancy interacts with environmental correlati…

- **[The Effective Reproduction Number in the Kermack-McKendrick model with age of infection and reinfection](https://arxiv.org/abs/2512.05889)**  
  _Mon, 08 Dec 2025 00:00:00 -0500_  
  arXiv:2512.05889v1 Announce Type: new 
Abstract: This study introduces a novel epidemiological model that expands upon the Kermack-McKendrick model by incorporating the age of infection and reinfection. By including infection age, we can classify participants, which enables a more targeted analysis within the modeling…

- **[Incorporating indel channels into average-case analysis of seed-chain-extend](https://arxiv.org/abs/2512.05247)**  
  _Mon, 08 Dec 2025 00:00:00 -0500_  
  arXiv:2512.05247v1 Announce Type: cross 
Abstract: Given a sequence $s_1$ of $n$ letters drawn i.i.d. from an alphabet of size $\sigma$ and a mutated substring $s_2$ of length $m < n$, we often want to recover the mutation history that generated $s_2$ from $s_1$. Modern sequence aligners are widely used for this task,…

- **[Enhancing Clinical Note Generation with ICD-10, Clinical Ontology Knowledge Graphs, and Chain-of-Thought Prompting Using GPT-4](https://arxiv.org/abs/2512.05256)**  
  _Mon, 08 Dec 2025 00:00:00 -0500_  
  arXiv:2512.05256v1 Announce Type: cross 
Abstract: In the past decade a surge in the amount of electronic health record (EHR) data in the United States, attributed to a favorable policy environment created by the Health Information Technology for Economic and Clinical Health (HITECH) Act of 2009 and the 21st Century C…

- **[The Great Oxidation Event (GOE): Biogeochemical Feedback and Tipping Points](https://arxiv.org/abs/2512.05305)**  
  _Mon, 08 Dec 2025 00:00:00 -0500_  
  arXiv:2512.05305v1 Announce Type: cross 
Abstract: Approximately 1.4 Ga after life first appeared, atmospheric oxygen suddenly jumped by more than an order of magnitude over a 20-50 Ma period. The contrast between these two timescales does not seem to be due to any sudden, large amplitude change in external forcing. H…

- **[Hypothesis-Based Particle Detection for Accurate Nanoparticle Counting and Digital Diagnostics](https://arxiv.org/abs/2512.05346)**  
  _Mon, 08 Dec 2025 00:00:00 -0500_  
  arXiv:2512.05346v1 Announce Type: cross 
Abstract: Digital assays represent a shift from traditional diagnostics and enable the precise detection of low-abundance analytes, critical for early disease diagnosis and personalized medicine, through discrete counting of biomolecular reporters. Within this paradigm, we pres…

- **[MCP-AI: Protocol-Driven Intelligence Framework for Autonomous Reasoning in Healthcare](https://arxiv.org/abs/2512.05365)**  
  _Mon, 08 Dec 2025 00:00:00 -0500_  
  arXiv:2512.05365v1 Announce Type: cross 
Abstract: Healthcare AI systems have historically faced challenges in merging contextual reasoning, long-term state management, and human-verifiable workflows into a cohesive framework. This paper introduces a completely innovative architecture and concept: combining the Model…

- **[Model Gateway: Model Management Platform for Model-Driven Drug Discovery](https://arxiv.org/abs/2512.05462)**  
  _Mon, 08 Dec 2025 00:00:00 -0500_  
  arXiv:2512.05462v1 Announce Type: cross 
Abstract: This paper presents the Model Gateway, a management platform for managing machine learning (ML) and scientific computational models in the drug discovery pipeline. The platform supports Large Language Model (LLM) Agents and Generative AI-based tools to perform ML mode…

- **[Mechanistic Interpretability of Antibody Language Models Using SAEs](https://arxiv.org/abs/2512.05794)**  
  _Mon, 08 Dec 2025 00:00:00 -0500_  
  arXiv:2512.05794v1 Announce Type: cross 
Abstract: Sparse autoencoders (SAEs) are a mechanistic interpretability technique that have been used to provide insight into learned concepts within large protein language models. Here, we employ TopK and Ordered SAEs to investigate an autoregressive antibody language model, p…
